Participants will learn about the prevalence, incidence, and economic impact of venous thromboembolism and atrial fibrillation on patients, as well as the associated treatments and clinical data relating to efficacy, safety, and cost-efficacy.
Charles E. Mahan, PharmD, RPh, PhC
Advertisement
Articles by Charles E. Mahan, PharmD, RPh, PhC
Advertisement
Latest Updated Articles
- The Impact of Direct Oral Anticoagulants in the Managed Care Environment
December 17th 2015
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs
2
Fourteen Years of HIV PrEP: How New Innovations Build on Decades of Progress in HIV
3
Oral COVID-19 PEP May Benefit High-Risk Groups More Than General Public: Peter J. Hotez, MD
4
EHA 2026 Had Something for Everyone, From Pediatric Practitioners to “Myeloma Maniacs”
5